Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (8 quarters reported)
$327M in Q4 2023 → $16.4M now. Hover for any quarter.
As reported for the quarter ended September 30, 2025. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| Ovid Therapeutics, Inc. | 59.8% | Unchanged | 7,531,996 | $9.79M |
| Equillium, Inc. | 15.9% | Unchanged | 1,824,977 | $2.61M |
| XT Xilio Therapeutics, Inc. (formerly Akrevia Therapeutics) | 7.6% | Unchanged | 1,475,121 | $1.24M |
| Shattuck Labs, Inc. | 7.5% | Unchanged | 515,619 | $1.23M |
| Lyell Immunopharma, Inc. | 5.4% | Added 33% | 54,887 | $891K |
| American Well Corporation | 2.9% | Unchanged | 77,733 | $478K |
| Rani Therapeutics Holdings, Inc. | 0.6% | Unchanged | 203,190 | $102K |
| Standard Biotools, Inc. | 0.1% | Unchanged | 16,515 | $21.5K |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 7 quarters.
quarter ended September 30, 2025 · filed November 13, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Hillevax, Inc. | Exited | −6,724,000 | −$13.4M | — |
| Turnstone Biologics | Exited | −895,824 | −$322K | — |
| Lyell Immunopharma, Inc. | Added | +13,722 | +$223K | 5.4% |
| Third Harmonic Bio, Inc. | Exited | −36,835 | −$200K | — |
quarter ended June 30, 2025 · filed August 08, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Lyell Immunopharma, Inc. | Trimmed | −782,152 | −$6.91M | 1.9% |
quarter ended March 31, 2025 · filed May 12, 2025
No position changes this quarter.
quarter ended December 31, 2024 · filed February 12, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Wave Life Sciences Ltd. | Exited | −1,346,892 | −$11M | — |
| Lyell Immunopharma, Inc. | New | +823,317 | +$527K | 2.0% |
| Third Harmonic Bio, Inc. | New | +36,835 | +$379K | 1.4% |
quarter ended September 30, 2024 · filed February 13, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Denali Therapeutics Inc. | Exited | −4,214,559 | −$97.9M | — |
| Phathom Pharmaceuticals, Inc. | Exited | −1,557,063 | −$16M | — |
| American Well Corp | Trimmed | −1,476,936 | −$14M | 1.9% |
| Akili, Inc. | Exited | −738,819 | −$321K | — |
| Rani Therapeutics Holdings, Inc. | Trimmed | −11,982 | −$25.9K | 1.2% |
quarter ended June 30, 2024 · filed February 13, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Phathom Pharmaceuticals, Inc. | Trimmed | −1,596,154 | −$16.4M | 6.9% |
| Shattuck Labs, Inc. | Trimmed | −985,442 | −$3.8M | 0.9% |
| Day One Biopharmaceuticals, Inc. | Exited | −85,840 | −$1.42M | — |
| Rani Therapeutics Holdings, Inc. | Trimmed | −123,507 | −$469K | 0.4% |
| AT Aerovate Therapeutics, Inc. | Exited | −13,580 | −$402K | — |
quarter ended March 31, 2024 · filed February 13, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Phathom Pharmaceuticals, Inc. | Trimmed | −4,306,069 | −$45.7M | 11.6% |
| Shattuck Labs, Inc. | Trimmed | −589,797 | −$5.27M | 4.6% |
| Day One Biopharmaceuticals, Inc. | New | +85,840 | +$1.42M | 0.5% |
Loading...
